Gehrmann et al. (1995) showed that the level of APP expression is correlated with histopathological lesion development; therefore, APP is an important biomarker for the progression of MS. Also, Matías-Guiu et al. (2016) stated APP has a role in both demyelination and remyelination. Variants of FN1 are shown to be associated with MS in the study of Dardiotis et al. (2019). Here, FN1 is linked to myeloid sarcoma.